November 20, 2015, Wellesley, MA & Reston, VA. Outcome Capital, an investment banking firm that serves middle market growth companies in life sciences and technology, today announced that Biosense Webster, Inc., part of the Johnson & Johnson Family of Companies, has acquired privately held Coherex Medical, Inc. Coherex’s flagship product, the minimally invasive WaveCrest® device, is designed to block the most common source of blood clots to prevent the occurrence of stroke in at-risk patients with atrial fibrillation (AF). Outcome Capital served as the exclusive strategic and financial advisor to Coherex Medical for the transaction.
“Arnold Freedman and Dr. Oded Ben-Joseph of Outcome Capital have demonstrated an astute and insightful understanding of our value proposal and the major companies in the cardiovascular space,” said Alex Martin, President and CEO of Coherex Medical. “They provided us with invaluable strategic advice and I can’t think of better partners to have guided us through the process.”
AF accounts for as much as 20% of all strokes and is the most common sustained cardiac arrhythmia. It is often a result of heart disease, high blood pressure, and aging. Patients with AF are at increased risk of developing clots, primarily formed in the left atrial appendage (LAA), which can enter the bloodstream and cause a stroke.
The Coherex WaveCrest System from Coherex Medical is an LAA occlusion device. Once implanted, it closes off the LAA to prevent the release of clots into the bloodstream. The device is uniquely designed to improve clinical outcomes through control of placement with retractable anchors; visualization of acute closure, position, and stability; and rapid endothelization. The Coherex WaveCrest System is made of material developed for its ability to minimize clot formation. Coherex has received CE Mark approval for the Coherex WaveCrest System.
“The Coherex WaveCrest System addresses many of the current challenges facing other devices developed for the reduction of stroke related to atrial fibrillation,” said Mr. Martin. “Biosense Webster has a proven track record of bringing quality treatments to patients suffering from heart rhythm disorders around the world, and we look forward to being part of this respected organization.”
About Outcome Capital
Outcome Capital is a unique investment banking firm that provides middle-market growth companies in the life sciences, healthcare services and technology markets with a value-added client-centric approach to merger, acquisition and corporate finance advisory services. The firm utilizes its proven approach to value enhancement by assisting boards and management teams in navigating both the financial and strategic markets and in implementing the best path for success. Outcome Capital’s strength stems from its unique ability to draw on its wide range of operational, strategic and transactional experience, its expertise across the value chain, and its broad industry relationships. The professionals at Outcome Capital take pride in their ability to help their clients to make well-informed strategic decisions and recognize the full value created by their vision. For more information, visit: outcomecapital.wpengine.com.
Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a leading provider of cancer registry solutions and compliance and informatics services, has been acquired by Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare technology and data analytics company with […]Read More
Outcome Capital Life Science Market Pulse October 2023 Click to view our LifeSciences Pulse NewsletterDownload